Gastroenteropancreatic Neuroendocrine Tumor – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapy and TPP Insights

Thelansis’s “Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Gastroenteropancreatic Neuroendocrine Tumor Overview

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies arising from neuroendocrine cells of the gastrointestinal tract and pancreas, differing substantially in grade, differentiation, somatostatin-receptor expression, hormone secretion, and metastatic behavior. Somatostatin analogs remain important for hormone control and tumor-growth suppression in appropriate well-differentiated disease, while targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT) are selected according to tumor biology and treatment history. PRRT with Lu-177-based agents has become a cornerstone for advanced somatostatin-receptor-positive NETs, with recent evidence supporting broader and more personalized use. The 2026 Phase 3 COMPETE trial directly compared Lu-177-edotreotide with everolimus in progressive SSTR-positive GEP-NETs, highlighting increasing emphasis on treatment sequencing and disease setting. Nevertheless, resistance, heterogeneous receptor expression, cumulative toxicity, and limited options after progression remain important unmet needs. Next-generation innovation is therefore extending the theranostic model through optimized dosimetry, combination strategies, and alpha-emitting radioligands that can deliver high-energy radiation to selected tumor cells. These approaches remain investigational and require validation of efficacy, safety, and patient selection. For stakeholders, GEP-NETs represent a high-value theranostic frontier where the next advances will depend on matching radionuclide properties and treatment sequencing to tumor biology while extending durable disease control.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)